Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22983071 | 0.75 | MCHR1 (0.40) | — | |
| SCHEMBL21176617 | 0.75 | DUT (0.38) | DUT | |
| SCHEMBL29786209 | 0.74 | CA12 (0.33) | CA12CA1CA9 | |
| SCHEMBL12633778 | 0.74 | TSHR (0.37) | — | |
| SCHEMBL2016743 | 0.74 | CA12 (0.42) | DUTCA12CA1CA2CA9 | |
| SCHEMBL25690640 | 0.74 | DUT (0.36) | DUTCA12CA1CA2CA9 | |
| SCHEMBL21468555 | 0.74 | — | — | |
| SCHEMBL23364754 | 0.74 | HRH3 (0.37) | — | |
| SCHEMBL21452755 | 0.73 | — | — | |
| SCHEMBL3435460 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| WO-2024171094-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | CDK2, CDK1, CCNK | DUT 659/4885CA12 4511/4885CA1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.